TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~De novo subjects:~* Seeking treatment for opioid use disorder (OUD) and for the previous 3 months meet the Diagnostic and Statistical Manual 5 (DSM-5) criteria for moderate or severe OUD~* Appropriate candidate for opioid partial-agonist treatment~* BMI between 18 and 35, inclusive~Roll-over subjects:~* Completed RB-US-13-0001~Exclusion Criteria:~De novo subjects:~* Current diagnosis, other than OUD, requiring chronic opioid treatment~* Current substance use disorder with regard to substances other than opioids, cocaine, cannabis, tobacco or alcohol~* Received medication-assisted treatment for OUD in the 90 days prior to informed consent~* Use (within past 30 days prior to informed consent) or positive urine drug screen (UDS) at screening for barbiturates, benzodiazepines,methadone or buprenorphine~* Treatment for OUD required by court order~* History of recent suicidal ideation or attempt~Roll over subjects:~* Experienced major protocol deviations or adverse events in RB-US-13-0001 which could potentially compromise subject safety~* Discontinued early from study RB-US-13-0001

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Roll-over Subjects (Type: EXPERIMENTAL): Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
- De Novo Subjects (Type: EXPERIMENTAL): Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer between 1 - 12 years old;~* Proven legal identity;~* Guardian(s) of the volunteer and/or volunteers themselves should be capable of understanding the written consent form, and such form should be signed before the volunteer being included into this study;~Exclusion Criteria:~* Prior vaccination with varicella vaccine or with history of varicella zoster virus (VZV) infection;~* Axillaty temperature \> 37.0 °C;~* History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc;~* History of epilepsy, seizures or convulsions, or a family history of mental illness, autoimmune disease or immunodeficiency;~* Severe malnutrition, congenital malformation, developmental disorders, or serious chronic diseases;~* Acute disease or acute stage of chronic disease within 7 days prior to study entry;~* Receipt of any of the following products:~  1. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;~ 2. Any live attenuated vaccine within 1 month prior to study entry;~ 3. Any blood product, immunosuppressant, hormone, or other investigational medicine(s) within 30 days prior to study entry;~* Any significant abnormity of heart, lung, skin, or pharynx;~* Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): * Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~* Intervention: investigational live attenuated varicella vaccine;
- Control Group (Type: SHAM_COMPARATOR): * Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~* Intervention: diluent of lyophilized vaccine;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of High Altitude Polycythemia by Acetazolamide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with Chronic mountain sickness and Hb \> 21g/dl~Exclusion Criteria:~* patients smokers~* patients with respiratory or cardiovascular or renal disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- acetazolamide (Type: PLACEBO_COMPARATOR): acetazolamide 250mg /day oral administration, for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Duration of Bupivacaine Spinal Block in Orthopedic Procedures With and Without Epinephrine Wash

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Patients scheduled for total hip or knee replacement~Exclusion Criteria:~* Patients taking anticoagulation~* Infection at or near the intended needle insertion site~* Patients with sacral decubitus ulcer at or near the intended needle insertion site aortic stenosis~* Complex spine anatomy~* ASA class greater than III~* Failed SAB as determined by the staff anesthesiologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bupivacaine Only (Type: PLACEBO_COMPARATOR): The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
- EPI25 group (Type: ACTIVE_COMPARATOR): The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
- EPI50 group (Type: ACTIVE_COMPARATOR): The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
- EPI75 group (Type: ACTIVE_COMPARATOR): The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
- EPI100 group (Type: ACTIVE_COMPARATOR): The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Gore SCAFFOLD Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years old at informed consent~* Patient is willing and capable of complying with all study protocol requirements, including specified follow-up period and can be contacted by telephone.~* Patient is willing to provide written informed consent prior to enrollment in study.~* Patient is either:~  * Symptomatic with carotid stenosis ≥50% as determined by angiography using NASCET methodology. Symptomatic is defined as amaurosis fugax ipsilateral to the carotid lesion; Transient Ischemic Attack (TIA) or non-disabling stroke within 180 days of the procedure within the hemisphere supplied by the target vessel; OR~ * Asymptomatic with carotid stenosis ≥80% as determined by angiography using NASCET methodology~* Patient must be considered high risk for adverse events during carotid endarterectomy~Note: Additional inclusion criteria may apply~Exclusion Criteria:~* Patient has life expectancy of less than one year.~* Patient is experiencing (or has experienced) an evolving, acute, or recent disabling stroke.~* Patient has anticipated or potential sources of emboli (e.g. atrial fibrillation, known previously symptomatic patent foramen ovale (PFO), mechanical heart valve, or Deep Vein Thrombosis (DVT) treated within 6 months).~* Patient has had an acute myocardial infarction within 72 hours prior to the index procedure.~* Patient has a history of major, disabling ipsilateral stroke with residual deficit that may confound the neurological subject assessments.~* Patient has known severe carotid stenosis contralateral to the target lesion requiring treatment within 30 days following the index procedure.~Note: Additional exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carotid Artery Stenting (Type: EXPERIMENTAL): Carotid Artery Stenting with the GORE® Carotid Stent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meets protocol-specified criteria for qualification and contraception, including treatment-resistant seizure disorder~* Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure~* In the opinion of the Investigator, the participants and parent(s)/caregiver(s) are willing and able to comply with the study procedures and visit schedules, including venipuncture, inpatient stay at the study center, dosing at the study center twice a day as needed while an outpatient), and the Follow-up Visits (if applicable)~Exclusion Criteria:~* Participant or parent(s)/caregiver(s) have daily commitments during the study duration that would interfere with attending all study visits~* History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters~* Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:~  1. the safety or well-being of the participant or study staff~ 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)~ 3. the analysis of results

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose Cannabidiol Oral Solution [10 mg/kg/day] (Type: EXPERIMENTAL): Low Dose \[10 milligrams/kilogram/day (mg/kg/day)\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
- Mid Dose Cannabidiol Oral Solution [20 mg/kg/day] (Type: EXPERIMENTAL): Mid Dose \[20 mg/kg/day\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
- High Dose Cannabidiol Oral Solution [40 mg/kg/day] (Type: EXPERIMENTAL): High Dose \[40 mg/kg/day\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Person who had a heart attack within 1 - 3 years ago and at least one additional risk factor: Age ≥ 65 years old, Diabetes requiring medication, Documented history of 2nd prior MI (\>1 year ago). Angiographic evidence of multivessel CAD, and / or Chronic, non-end stage renal dysfunction.~* Females of child-bearing potential must have a negative pregnancy test at enrollment~* Persons who are currently taking aspirin between 75 and 150 mg once daily~Exclusion Criteria:~* Persons who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start~* Persons who have planned coronary, cerebrovascular, or peripheral arterial Revascularization (invasive surgery) at study start~* Persons with known bleeding disorders~* Persons who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin~* Persons with a history of ischemic stroke~* Persons with a history of intracranial bleeding at any time, a tumor or blood vessel abnormality in the brain and/or spinal cord at any time, a history of surgery involving the brain or spinal cord within the last 5 years, or a history of bleeding from the gastrointestinal tract (eg, esophagus, stomach, colon, rectum) within the last 6 months or a major surgery within the last 30 days.~* Persons considered to be at risk of bradycardic events unless already treated with a permanent pacemaker~* Persons who have had open heart surgery within the past 5 years, unless the person had a heart attack after the surgery~* Persons with known severe liver disease~* Persons with kidney failure requiring dialysis~* Persons with life expectancy \< 1 year

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral Treatment
- 2 (Type: EXPERIMENTAL): Oral Treatment
- 3 (Type: PLACEBO_COMPARATOR): Oral Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of moderately severe or severe hemophilia B (FIX:C less than or equal to 2%)~* Male subjects, aged 6 years to 65 years.~* Subjects with a minimum of 12 bleeding episodes, 6 of which must be joint bleeds, in the 12 months before screening.~Exclusion Criteria:~* Subjects currently utilizing FIX primary prophylaxis.~* Subjects with HIV+ who have a CD4 count less than 200~* Subjects with hepatic or renal impairment.~* Prothrombin time or International Normalized Ration more than 1.5 times the upper limit of normal.~* Major surgery or an orthopedic surgical procedure within the past 3 months or is planned within the duration of participation in this study.~* Past history of, or current FIX inhibitor.~* Hypersensitivity to any FIX product or hamster protein.~* Exposure to any investigational drug, except for rFIX-R, or device within 30 days of providing consent/assent (as appropriate) for this study.~* Bleeding disorders other than hemophilia B.~* Concurrent inflammatory disease that in the investigator's judgment could confound the study results.

- Gender: MALE
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aggressive Antipyretics for Fever Reduction in CNS Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of Plasmodium falciparum malaria infection by peripheral blood smear or rapid diagnostic test~* Central nervous system (CNS) symptoms associated with malaria. CEREBRAL MALARIA (CM): Impaired consciousness with a Blantyre Coma Score (BCS)(73) ≤2 in children under 5 years or a Glasgow Coma score (GCS) ≤10 in children ≥5 years OR CNS MALARIA: Complicated seizure(s), meaning prolonged (\>15 minutes), focal or multiple; or impaired consciousness or other evidence of impaired consciousness (confusion, delirium) without frank coma (BCS\>2, GCS =11-14)~Exclusion Criteria:~* Circulatory failure (cold extremities, capillary refill \> 3 seconds, sunken eyes, ↓ skin turgor)~* Vomiting in the past 2 hours~* Serum creatinine (Cr) \> 1.2 mg/dL~* A history of liver disease~* Jaundice or a total bilirubin of \>3.0mg/dL~* A history of gastric ulcers or gastrointestinal bleeding~* A history of thrombocytopenia or other primary hematologic disorder~* Petechiae or other clinical indications of bleeding abnormalities~* A known allergy to ibuprofen, acetaminophen, aspirin or any non-steroidal medication~* Any contraindication for nasogastric tube (NGT) placement and/or delivery of enteral medications

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Aggressive Antipyretics (Type: EXPERIMENTAL): regardless of temperature, children allocated to this arm will receive acetaminophen (30 milligrams (mg)/ kilogram (kg) load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
- Usual Care (Type: PLACEBO_COMPARATOR): will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIV Risk Reduction and Drug Abuse Treatment in Malaysia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Opioid dependence~Exclusion Criteria:~* Dependence on alcohol, benzodiazepines or sedatives~* Suicide or homicide risk~* Psychotic disorder or major depression~* Inability to read or understand the protocol or assessment questions~* Life-threatening or unstable medical problems~* Greater than 3 times normal liver enzymes (AST, GGT)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* No prior treatment with botulinum toxin Type A for treatment of iOAB~Exclusion Criteria:~* Treatment with any botulinum toxin Type A within 18 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients With Urinary Incontinence Due to iOAB (Type: None): Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Stroke Aphasia and Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* LMCA stroke as indicated by the presence of aphasia and MRI lesion in the LMCA distribution~* Moderate aphasia (Token Test score between 40th and 90th percentile)~* Fluency in English~* Provision of written informed consent by the patient and/or the next of kin~Exclusion Criteria:~* Age less than 18 years~* Underlying degenerative or metabolic disorder or supervening medical illness~* Severe depression or other psychiatric disorder~* Positive pregnancy test in women of childbearing age~* Any contraindication to MRI/fMRI at 3T (i.e., intracranial metal implants, claustrophobia)~* Any contraindication to nerTMS (e.g., seizures or epilepsy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rTMS (Type: EXPERIMENTAL): 3 weeks of nerTMS
- 1 week of Sham Treatment + 2 weeks of nerTMS (Type: SHAM_COMPARATOR): 1 week of Sham Treatment + 2 weeks of nerTMS
- 2 weeks of Sham Treatment +1 week of nerTMS (Type: SHAM_COMPARATOR): 2 weeks of Sham Treatment +1 week of nerTMS
- Control Group (Type: PLACEBO_COMPARATOR): 3 weeks of Sham Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete